iiinova — where your digital self keeps evolving

John De Vos @jdevos.bsky.social · 17/09/2026

Fate’s #ACR2026 studies suggest #iPSC-derived #CARTs could become a compelling allogeneic platform: a potentially unlimited supply of a standardized, homogeneous product. Data cover FT819 in lupus - without conditioning/outpatient use - and CD19/CD38 FT839 in RA. buff.ly/1U7ulvd

000

John De Vos @jdevos.bsky.social · 16/09/2026

Very nice review by @Joseph_C_Wu et al. on the use of #iPSCells in medicine, including manufacturing complexities. buff.ly/1rF5Czk

000

John De Vos @jdevos.bsky.social · 15/09/2026

Early but promising results with armored #CARTcells targeting glypican-3 and co-expressing IL-15 and IL-21 in pediatric hepatoblastoma. Step by step, CAR-T cells are beginning to make solid tumors addressable. buff.ly/ZqJ8UbH

000

John De Vos @jdevos.bsky.social · 11/09/2026

Craig Venter passed away. I'm old enough to remember the sequencing of the genome in 2001, by the team of Craig Venter (Celera Genomics), the Science cover, and an International public consortium, the Nature cover. buff.ly/InQ8izN

000

John De Vos @jdevos.bsky.social · 08/09/2026

In a Phase II trial for idiopathic pulmonary fibrosis, rentosertib reportedly lowered proteomic biological age in the treated group—potentially signalling disease regression, systemic rejuvenation, or both. If confirmed, this could be a landmark advance in gerobiology. buff.ly/WSFNu7T

010

John De Vos @jdevos.bsky.social · 01/09/2026

⚠️ A reminder that #CARTcells expansion beyond cancer comes with real safety challenges. Novartis has paused 8 trials of its CAR-T therapy in autoimmune diseases after 3 patients died following severe immune reactions. A major setback for an otherwise highly promising field. buff.ly/ApFP5Iy

000

John De Vos @jdevos.bsky.social · 25/08/2026

🧬 Connecting new ideas in Stem Cell Biology! Join leading scientists from Europe, Canada & the U.S. for the 6th International Conference on developmental, adult and cancer Stem Cells. 📍 Lyon, France 📅 October 1–2, 2026 By Aurastem buff.ly/NRKL0Pg #StemCells, #Development and #Cancer

000

John De Vos @jdevos.bsky.social · 12/08/2026

Anti-CD19 #CARTCells can persist up to 10 years after infusion in patients with lymphoid malignancies. In one patient CART cells comprised 1.2% of circulating T cells at 9y. Long-term persisting CART cells were predominant double-negative (CD4−CD8−), effector-memory-like phenotype. buff.ly/FBYeuwR

000

John De Vos @jdevos.bsky.social · 10/08/2026

Encouraging results for CAR-T in recurrent glioblastoma: intracranial B7-H3 CAR-T (TX103) was well tolerated in a Phase 1 trial (n=15), with no DLTs. Median OS reached 19.1 months, with 66.7% alive at 12 months and one sustained complete response. Phase 2 warranted. #CARTcells buff.ly/1hWb3c9

000

John De Vos @jdevos.bsky.social · 10/08/2026

‘A chilling effect’: China biotech will slow as it nears R&D frontier, Pfizer’s Baum predicts . buff.ly/VydvQje/

020

John De Vos @jdevos.bsky.social · 30/07/2026

Global warming is already harming human health in countless ways. We can now add smoke-related deaths to the growing list. By David Wallace-Wells of the NYT. www.nytimes.com/2026/07/22/o...

010

John De Vos @jdevos.bsky.social · 20/07/2026

📣 SAVE THE DATE! The 8th FSSCR Meeting will be held in Paris from Tuesday 11 to Thursday 13 May 2027. As usual, our scientific committee is curating an exceptional lineup of prestigious speakers (to be announced soon) from some of the most renowned research centres. STAY TUNED. #FSSCR #StemCells

031

John De Vos @jdevos.bsky.social · 15/07/2026

In June, genome-editing pioneer Sangamo Therapeutics filed for bankruptcy. A change of era for one of the field's early trailblazers. buff.ly/wgGhrdh

000

John De Vos @jdevos.bsky.social · 08/07/2026

Encouraging early clinical data for #iPSC-derived #CART therapy in autoimmune disease. Off-the-shelf FT819 showed promising activity in systemic sclerosis patients, with no CRS, ICANS or GvHD reported. A potential step toward on-demand CAR-T. #CellTherapy #ISSCR2026

100

John De Vos @jdevos.bsky.social · 08/07/2026

📢 Les inscriptions au Diplôme Universitaire « Thérapies Cellulaire & Génique – Médecine Régénératrice » de la Faculté de Médecine de Montpellier sont ouvertes! 📅 Formation intensive du 9 au 20 novembre 2026 💻 Accessible en présentiel ou en distanciel 😀 Inscriptions : buff.ly/5jebkp6

000

John De Vos @jdevos.bsky.social · 26/06/2026

Exciting conference in Paris! 📅 21–22 September 2026 Cell plasticity in Development and Disease. #SFBD #FSSCR IT cell biology, reproduction, development and evolution

042

John De Vos @jdevos.bsky.social · 14/06/2026

010

John De Vos @jdevos.bsky.social · 08/06/2026

CAR T-cell therapy is able to deplete anti-HLA antibodies. Combining CAR T cells directed against CD19 and against BCMA resulted in successful kidney transplantation in two highly sensitized patients. buff.ly/AycIPHs

020

John De Vos @jdevos.bsky.social · 03/06/2026

I’m curious to know whether there’s any chance these treatments might work.

020

John De Vos @jdevos.bsky.social · 28/05/2026

🧬 Envie de vous former aux thérapies cellulaires, géniques et à la médecine régénératrice ? Le DU de la Faculté de Médecine de Montpellier revient du 9 au 20 novembre 2026, en présentiel ou distantiel 😀. Au programme : cellules souches, CRISPR, CART, organoïdes, MTI… Inscription: buff.ly/qhKJV8X

000

John De Vos @jdevos.bsky.social · 07/05/2026

AI outperforms clinicians in conducting patient clinical interviews! buff.ly/gMhkSXL

000

John De Vos @jdevos.bsky.social · 05/05/2026

Century Therapeutics will present CNTY-813, its #iPSCells-derived islet replacement therapy for T1D, at #ADA2026 June, New Orleans. The Allo-Evasion™ 5.0, off-the-shelf beta islet platform aims to reduce or eliminate the need for chronic immunosuppression. IND -> Q4 2026. buff.ly/98QdSWJ

000

John De Vos @jdevos.bsky.social · 24/03/2026

Join us June 23–24, 2026, Montpellier, for this first‑edition Complex Organoid Systems with Multifaceted InteraCtions Symposium. Invited speakers : Katja Wolthers | Amsterdam Simon Schäfer | Germany Céline Cougoule | Toulouse Alexandre Grassart | Lille #Organoids buff.ly/wsgMCQg

053

John De Vos @jdevos.bsky.social · 18/03/2026

Positive Phase I/II results from Aspen using autologous #iPSCells-derived dopaminergic neuron precursors for surgical treatment of Parkinson’s disease. Pivoting to phase III. Very promising! buff.ly/Z6ItRnM

011

John De Vos @jdevos.bsky.social · 04/03/2026

📣 📣 📣 World first!! Japan’s health ministry has granted a provisional 7-year approval for the commercialization of two regenerative medicine products derived from #iPSCells, aimed at treating ischemic cardiomyopathy and Parkinson’s disease. buff.ly/nAKKmib

000

John De Vos @jdevos.bsky.social · 19/02/2026

A first-in-human #GeneTherapy clinical trial is being launched to evaluate partial cellular reprogramming of the eye using AAV delivery of OCT4, SOX2, & KLF4 under doxycycline control, targeting two forms of age-related vision loss. Based on the work of David Sinclair (Harvard). buff.ly/uV4kbgU

021

John De Vos @jdevos.bsky.social · 09/01/2026

Other data regarding #CARTCell treatments in France. Interesting! Source : buff.ly/k3Z9kDv

010

John De Vos @jdevos.bsky.social · 08/01/2026

Number of #CARTCell treatments in France : rapidly increasing. Source : buff.ly/k3Z9kDv

020

John De Vos @jdevos.bsky.social · 24/12/2025

A phase II trial using #CART cells against a solid tumor (glioblastoma). T-MAXIMUM Pharmaceutical announced that its proprietary allogeneic B7-H3–targeted CAR-T therapy, MT027, has received FDA IND clearance. buff.ly/wiGPeyR

010

John De Vos @jdevos.bsky.social · 19/11/2025

Our meeting has now come to a close. Many thanks to all attendees and our outstanding speakers. See you in Paris in 2027! #FSSCR2025 Lyon, Nov 17–19, 2025

020

John De Vos @jdevos.bsky.social · 19/11/2025

The FSSCR Best Short Talk and Best Poster prizes — sponsored by the Fondation Marion & Elisabeth Brancher and Development — were awarded by Anne Camus and @crougeulle.bsky.social. Bravo to the winners! #FSSCR2025 Lyon, Nov 17–19, 2025

130

John De Vos @jdevos.bsky.social · 19/11/2025

Today, #FSSCR is tuning in to pluripotent stem cells… and their mechanical properties in plants! 🌱🔬 Who said curiosity has boundaries? Pradeep Das (ENS Lyon) presenting. #FSSCR2025 Lyon, Nov 17–19, 2025 coms.events/fsscr25/inde...

051

John De Vos @jdevos.bsky.social · 18/11/2025

Agathe Coeur presenting her work on improving NKX2.1+ lung progenitors production using a design of experiment (DOE) approach, at the FSSCR meeting. Thumbs up! #FSSCR2025 ✨🔬 Exciting #StemCell science ahead! Lyon, Nov 17–19, 2025 Full program here 🫵 buff.ly/kLeH5ET

020

John De Vos @jdevos.bsky.social · 18/11/2025

Nancy Mah (X : @NancyScience ) presenting the past and current pluripotent stem cell clinical trials worldwide. Clinical applications are coming! #FSSCR2025 ✨🔬 Exciting #StemCell science ahead! Lyon, Nov 17–19, 2025 Full program here 🫵 buff.ly/kLeH5ET

000

John De Vos @jdevos.bsky.social · 18/11/2025

The second day of the #FSSCR2025 meeting is starting by an exciting presentation on adult neurogenesis in vertebrates by @zaycha.bsky.social. ✨ #StemCell science Lyon, Nov 17–19, 2025 🫵 coms.events/fsscr25/inde...

042

John De Vos @jdevos.bsky.social · 17/11/2025

@karinayaniv.bsky.social share her work on the lymphatic lineage and cell fate (completely underestimated cell type), using zebrafish models but also ESC. Very beautiful work. #FSSCR2025 ✨ Exciting #StemCell science ahead! Lyon, Nov 17–19, 2025 🫵 coms.events/fsscr25/inde...

021

John De Vos @jdevos.bsky.social · 17/11/2025

Pierre Savatier discussing his recent results on inter-species chimeras, including those based on rabbit blastocysts, and based on primate (human and non-human) naive #iPSCells. #FSSCR2025 ✨🔬 Exciting #StemCell science ahead! Lyon, Nov 17–19, 2025 Full program here 🫵 buff.ly/kLeH5ET

131

John De Vos @jdevos.bsky.social · 17/11/2025

@hansclevers.bsky.social with full creativity at #FSSCR2025! Thanks to him to share his research with the audience. #FSSCR2025 ✨🔬 Exciting #StemCell science ahead! Lyon, Nov 17–19, 2025 Full program here 🫵 buff.ly/kLeH5ET

051

John De Vos @jdevos.bsky.social · 17/11/2025

The 7th #FSSCR Annual Meeting is starting today! Welcome to all of you. ✨🔬 Exciting #StemCell science ahead! Lyon, Nov 17–19, 2025 Full program here 🫵 buff.ly/kLeH5ET

030

John De Vos @jdevos.bsky.social · 17/11/2025

The iPSC platform session now! Lead by Laurent David 🙏 The 7th #FSSCR Annual Meeting is starting today! ✨🔬 Exciting #StemCell science ahead! Lyon, Nov 17–19, 2025 #FSSCR2025 😍 Full program here 🫵 buff.ly/I7w5Vyy

021

John De Vos @jdevos.bsky.social · 17/11/2025

The 7th #FSSCR Annual Meeting is starting today! Welcome to all of you. ✨🔬 Exciting #StemCell science ahead! Lyon, Nov 17–19, 2025 Use the hashtag #FSSCR2025 😍 Full program here 🫵 coms.events/fsscr25/en/d...

073

John De Vos @jdevos.bsky.social · 05/11/2025

✨🔬 Get ready for groundbreaking #StemCell research! Join us in Lyon, Nov 17–19, 2025, for the 7th #FSSCR Annual Meeting. Connect with leading experts and be part of inspiring scientific exchanges 👇 👉 buff.ly/FRotkAi @FSSCR_officiel #FSSCR2025

041

John De Vos @jdevos.bsky.social · 05/11/2025

✨🔬 Exciting #StemCell science ahead! Join us in Lyon, Nov 17–19, 2025 for the 7th #FSSCR Annual Meeting. Meet top speakers and take part in inspiring discussions 👇 👉 buff.ly/FRotkAi @FSSCR_officiel #FSSCR2025

020

John De Vos @jdevos.bsky.social · 30/10/2025

044

John De Vos @jdevos.bsky.social · 27/10/2025

#iPSC-derived, off-the-shelf anti-CD19 #CARTcells deliver improved clinical outcomes in lupus. buff.ly/h2uH87G

000

John De Vos @jdevos.bsky.social · 27/10/2025

021

John De Vos @jdevos.bsky.social · 24/10/2025

✨🔬Great #StemCell research. Come, discuss, join us in Lyon Nov 17-19, 2025 at the 7th #FSSCR annual meeting. Outstanding talks, see speakers: 👉https://buff.ly/FRotkAi 📆 Regular rates available until 19 Oct 2025 @FSSCR_officiel #FSSCR2025

020

John De Vos @jdevos.bsky.social · 21/10/2025

Galapagos exits the cell therapy field, joining other recent high-profile departures such as Novo Nordisk and Takeda. Tough times for the sector. buff.ly/x1igaTU

010

John De Vos @jdevos.bsky.social · 20/10/2025

Anti-BCMA #CARTells therapy in patients with progressive multiple sclerosis. Encouraging phase I study in 5 patients. via @CellCellPress buff.ly/tK6QG6D

000